High-throughput viral antibody discovery.
ANTYGEN™ VirScan™ service, co-developed by CDI’s Scientific Advisory Board Member Ben Larman, provides an unparalleled way to assay a patient’s viral history by comprehensively analyzing antiviral antibodies to a phage library displaying peptides from over 1300 strains of viruses — nearly every virus annotated to have human tropism in the UniProt database. This product is available as a service to both academic and industry customers.
While we are still in the process of adding SARS-CoV-2 peptides directly to the VirScan™ assay, SARS-CoV, MERS, and many other related coronaviruses are already contained in our “human virome” VirScan antibody detection assay.
The standard VirScan™ assay can be paired with one of our two SARS-CoV-2 microarrays: